Compare JBSS & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBSS | ESPR |
|---|---|---|
| Founded | 1959 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 873.7M | 898.5M |
| IPO Year | 1991 | 2013 |
| Metric | JBSS | ESPR |
|---|---|---|
| Price | $70.68 | $3.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $109.00 | $6.67 |
| AVG Volume (30 Days) | 56.4K | ★ 5.1M |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | ★ 21.12 | N/A |
| EPS | ★ 5.62 | N/A |
| Revenue | ★ $1,129,733,000.00 | $303,802,000.00 |
| Revenue This Year | $5.40 | $26.11 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | 1.88 | ★ 2.83 |
| 52 Week Low | $58.47 | $0.69 |
| 52 Week High | $91.26 | $4.13 |
| Indicator | JBSS | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 51.41 |
| Support Level | $75.53 | $3.87 |
| Resistance Level | $72.68 | $4.05 |
| Average True Range (ATR) | 1.80 | 0.20 |
| MACD | -0.74 | -0.05 |
| Stochastic Oscillator | 3.99 | 21.00 |
John B Sanfilippo & Son Inc is one of the processors and distributors of peanuts, pecans, cashews, walnuts, almonds, and other nuts in the United States. These nuts are sold under a variety of private brands and the Fisher, Orchard Valley Harvest, and Sunshine Country brand names. It also markets and distributes, and in the majority of cases, manufactures or processes, a diverse product line of food and snack products, including peanut butter, almond butter, cashew butter, candy and confections, snacks and trail mixes, snack bites, sunflower kernels, dried fruit, corn snacks, sesame sticks and other sesame snack products under private brands and brand names.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.